Omeros (OMER) PT Raised to $32 at Needham & Company Into Spring U.S. Launch of Omidria

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. LVS
9. QGEN
10. SPCX

Go back to Omeros (OMER) PT Raised to $32 at Needham & Company Into Spring U.S. Launch of Omidria

Omeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results

March 16, 2015 4:05 PM EDT

SEATTLE, March 16, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2014, which include:

Net loss in 4Q 2014 of $20.7 million or $0.61 per share and, for the full year of 2014, a net loss of $73.7 million or $2.22 per share Operating expenses in 4Q 2014 were... More